Clinical Trial Update: Dapagliflozin for Long COVID Syndrome [Phase 3]

View source ↗

Summary

The update announces a Phase 3 trial evaluating dapagliflozin for long COVID syndrome (post-acute sequelae of SARS-CoV-2 infection), currently not yet recruitin…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Post-acute Sequelae of Sars-cov-2 Infection

Drugs mentioned

• Dapagliflozin (dapagliflozin)
• FARXIGA (dapagliflozin)

Snippet

Sponsor: Ottawa Heart Institute Research Corporation | Conditions: COVID - 19, Long COVID Syndrome | Phase 3 | Status: NOT_YET_RECRUITING